Full Text of HR0138 102nd General Assembly
HR0138 102ND GENERAL ASSEMBLY |
| | HR0138 | | LRB102 17334 MST 22824 r |
|
| 1 | | HOUSE RESOLUTION
| 2 | | WHEREAS, Precision medicine, which is also called | 3 | | personalized health care or individualized medicine, is an | 4 | | evolving field in which healthcare providers use analysis of a | 5 | | patient's biospecimen, known as biomarker testing, to | 6 | | determine which medical treatments will work best for each | 7 | | patient; and
| 8 | | WHEREAS, By combining the data from biomarker testing with | 9 | | an individual's medical history, circumstances, and values, | 10 | | healthcare providers can direct a patient to targeted | 11 | | treatment, which benefits both patients and the overall | 12 | | healthcare system; and
| 13 | | WHEREAS, The field of precision medicine holds great | 14 | | promise in ensuring the delivery of the right treatment to the | 15 | | right patient at the right time; and
| 16 | | WHEREAS, Sixty percent of treatments in preclinical | 17 | | development rely on biomarker data; and | 18 | | WHEREAS, Biomedicine and the understanding of the | 19 | | characteristics of a patient's disease that informs precision | 20 | | medicine is evolving rapidly; and |
| | | HR0138 | - 2 - | LRB102 17334 MST 22824 r |
|
| 1 | | WHEREAS, Healthcare providers are increasingly gaining | 2 | | access to new technologies, such as biomarker testing, that | 3 | | can help identify gene mutations, alterations, or protein | 4 | | expressions specific to individual patients; and | 5 | | WHEREAS, Health outcomes are improved through the use of | 6 | | precision medicine; for example, patients with certain types | 7 | | of lung cancer who received biomarker testing had a 28 percent | 8 | | reduction in mortality; and | 9 | | WHEREAS, The National Academy of Medicine considers | 10 | | biomarker tests to be "key to unlocking the promise" of | 11 | | personalized health care; and | 12 | | WHEREAS, Biomarker testing is available for an | 13 | | ever-increasing range of conditions and diseases, but patient | 14 | | access to these tests is not keeping pace with the rate of | 15 | | innovation; and | 16 | | WHEREAS, A lack of awareness among providers and patients, | 17 | | a lack of common terminology, and deficient coverage policies | 18 | | by both public and private payers are preventing effective | 19 | | adoption and integration of biomarker testing into precision | 20 | | medicine and appropriate awareness and education about the | 21 | | ways biomarker testing can be used to support diagnosis, | 22 | | treatment, and monitoring of patients in a personalized way; |
| | | HR0138 | - 3 - | LRB102 17334 MST 22824 r |
|
| 1 | | and
| 2 | | WHEREAS, The Illinois Department of Public Health and | 3 | | other relevant partners seek to promote awareness, education, | 4 | | and action related to improving access to biomarker testing; | 5 | | therefore, be it
| 6 | | RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE | 7 | | HUNDRED SECOND GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that | 8 | | we declare March 2021 as "Precision Medicine and Biomarker | 9 | | Testing Awareness Month" to raise awareness, encourage | 10 | | education, and improve understanding of the ways biomarker | 11 | | testing can be used to support diagnosis, treatment, and | 12 | | monitoring of patients in a personalized way and the | 13 | | importance of ensuring access to these promising technologies.
|
|